On August 7, AKESO rose 3.28% in regular trading, trading at 99.55 HKD/share, with turnover of approximately 3.9 billion HKD.

On the news front, the company's overseas partner Summit recently announced the initiation of an international Phase II/III registrational clinical study evaluating ivonescimab plus enfortumab vedotin head-to-head against pembrolizumab plus enfortumab vedotin as first-line treatment for locally advanced or metastatic urothelial carcinoma. This marks the 16th registrational or Phase III clinical study for ivonescimab, the 6th international multi-center registrational study, and represents a key step in the company's IO2.0+ADC2.0 strategy in urologic oncology.

The study further expands ivonescimab's global clinical footprint following updated HARMONi Phase III data showing an overall survival hazard ratio of 0.76 in Western patients, which validated cross-ethnic efficacy consistency. The broader biotechnology sector also traded positively, with peers such as Remegen up 6.42% and Zai Lab up 15.55%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)